References
- Summary of Product Characteristics: trasylol® (aprotinin). 2013. [cited 2023 April 5]. https://www.medicines.org.uk/emc/product/2472
- EMA. Antifibrinolytics containing aprotinin, aminocaproic acid and tranexamic acid. Aprotinin. Assessment report. 2013. [cited 2023 April 5]. https://www.ema.europa.eu/en/documents/referral/assessment-report-antifibrinolytic-medicines-aprotinin_en.pdf
- Royston D, Bidstrup BP, Taylor KM, et al. Effect of aprotinin on need for blood transfusion after repeat open-heart surgery. Lancet. 1987;2(8571):1289–1291. doi: 10.1016/s0140-6736(87)91190-1.
- Mangano DT, Tudor IC, Dietzel C. The risk associated with aprotinin in cardiac surgery. N Engl J Med. 2006;354(4):353–365. doi: 10.1056/NEJMoa051379.
- Schneeweiss S, Seeger JD, Landon J, et al. Aprotinin during coronary-artery bypass grafting and risk of death. N Engl J Med. 2008;358(8):771–783. doi: 10.1056/NEJMoa0707571.
- Shaw AD, Stafford-Smith M, White WD, et al. The effect of aprotinin on outcome after coronary-artery bypass grafting. N Engl J Med. 2008;358(8):784–793. doi: 10.1056/NEJMoa0707768.
- Fergusson DA, Hébert PC, Mazer CD, et al. A comparison of aprotinin and lysine analogues in high-risk cardiac surgery. N Engl J Med. 2008;358(22):2319–2331. doi: 10.1056/NEJMoa0802395.
- Bayer Inc. Important safety information and availability of trasylol (aprotinin) - Notice to Hospitals. 2007. [cited 2023 April 5]. https://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2007/14481a-eng.php
- EMA. European medicines agency recommends suspension of marketing authorisation aprotinin-containing medicines for systemic use. European Medicines Agency. 2007. [cited 2023 April 5]. https://www.ema.europa.eu/en/news/european-medicines-agency-recommends-suspension-marketing-authorisation-aprotinin-containing
- EMA. Antifibrinolytics containing aprotinin, aminocaproic acid and tranexamic acid. Aprotinin. Annex IV. 2013. [cited 2023 April 5]. https://www.ema.europa.eu/en/documents/referral/antifibrinolytic-medicines-article-31-referral-annex-iv-aprotinin_en.pdf
- EMA. European medicines agency recommends lifting suspension of aprotinin. 2012. [cited 2023 April 5]. https://www.ema.europa.eu/en/news/european-medicines-agency-recommends-lifting-suspension-aprotinin
- McMullan V, Alston RP. III aprotinin and cardiac surgery: a sorry tale of evidence misused. Br J Anaesth. 2013;110(5):675–678. doi: 10.1093/bja/aet008.
- Royston D, De Hert S, van der Linden J, et al. A special article following the relicence of aprotinin injection in Europe. Anaesth Crit Care Pain Med. 2017;36(2):97–102. doi: 10.1016/j.accpm.2017.02.001.
- De Hert S, Ouattara A, Royston D, et al. Use and safety of aprotinin in routine clinical practice: a european postauthorisation safety study conducted in patients undergoing cardiac surgery. Eur J Anaesthesiol. 2022;39(8):685–694. doi: 10.1097/EJA.0000000000001710.
- Nashef SA, Roques F, Sharples LD, et al. EuroSCORE II. Eur J Cardiothorac Surg. 2012;41(4):734–745. doi: 10.1093/ejcts/ezs043.
- Bridgewater B, Kinsman R, Walton P, et al. The 4th european association for cardio-Thoracic surgery adult cardiac surgery database report. Interact Cardiovasc Thorac Surg. 2011;12(1):4–5. doi: 10.1510/icvts.2010.251744.
- Royston D. Aprotinin versus lysine analogues: the debate continues. Ann Thorac Surg. 1998;65(4 Suppl):S9–S19. doi: 10.1016/s0003-4975(98)00071-x.
- Aronson S, Fontes ML, Miao Y, et al. Risk index for perioperative renal dysfunction/failure; critical dependence on pulse pressure hypertension. Circulation. 2007;115(6):733–742. doi: 10.1161/CIRCULATIONAHA.106.623538.
- Lindvall G, Sartipy U, Ivert T, et al. Aprotinin is not associated with postoperative renal impairment after primary coronary surgery. Ann Thorac Surg. 2008;86(1):13–19. doi: 10.1016/j.athoracsur.2008.03.033.
- O'Connor CJ, Brown DV, Avramov M, et al. The impact of renal dysfunction on aprotinin pharmacokinetics during cardiopulmonary bypass. Anesth Analg. 1999;89(5):1101–1107. doi: 10.1213/00000539-199911000-00006.